NOVO NORDISK DIABETES CARE PRODUCT SALES INCREASE 9% TO $1.07 BIL.: COMPANY SEES 10% REVENUE GROWTH FOR 1995; CHIRON BETASERON SALES TO BERLEX TOP $100 MIL.
Executive Summary
Novo Nordisk diabetes care sales increased 9% in 1994 to $1.07 bil. (6.5 bil. Danish kroner) despite supply problems in the U.S., the company reported